April 17 – 18, 2025 | Washington D.C. | LUNGevity Foundation Early Lung Cancer Center Multi-Stakeholder Meeting April 22, 2025 | Boulder, CO | BizWest CEO Roundtable on Life Sciences April 23 – 24, 2025 | Baltimore, MD | 2025 Interventional Pulmonary Outcomes Group Annual Research Symposium April 25 – 30, 2025 | Chicago, IL | AACR Annual Meeting

Presentation on April 28 @ 12:30 PM in Spotlight Theater A: Developing Multi-Modal MRD and ctDNA Tests for Use in Clinical Research: Droplet Digital PCR-Driven Mutation and Methylation Quantification, CTCs and Proteomics by Gary Pestano, Ph.D., Biodesix Chief Development Officer and other speakers. Sponsored by Bio-Rad.

May 6, 2025 | Denver, CO | 2025 Structural Biology, Biochemistry and Biophysics Symposium at the University of Colorado, Anschutz Campus May 16 – 21, 2025 | San Francisco, CA | ATS 2025 International Conference May 13 – 16, 2025 | Montreal, QC, Canada | ISPOR May 19, 2025 | San Francisco, CA | Society for Advanced Bronchoscopy at ATS May 30 – June 3, 2025 | Chicago, IL | 2025 ASCO Annual Meeting June 1 – 5, 2025 | Baltimore, MD | 73^rd Conference on Mass Spectrometry and Allied Topics June 16 – 19, 2025 | Boston, MA | BIO 2025

Panel Discussion on June 17 @ 11 AM: Advancing Innovative Risk-Stratification Tests that Impact Treatment Pathway Decisions: Challenges in Overcoming Barriers to Entry with Robin Harper Cowie, Chief Financial Officer, Biodesix, and other speakers.

June 24, 2025 | Denver, CO | Mountain West BioLife Summit

Presentation and panel hosted by Brianna Phillips, VP Quality & Regulatory, Biodesix

June 26 – 28, 2025 | Nashville, TN | 2nd Annual APAPP National Conference August 14 – 16, 2025 | Austin, TX | AABIP 6^th Annual Conference September 22 – 25, 2025 | Boston, MA | 15^th Annual World CB & CDx Summit October 9 – 11, 2025 | Denver, CO | Go2 2025 Centers of Excellence Summit October 19 – 22, 2025 | Chicago, IL | CHEST 2025 November 7 – 8, 2025 | Charlotte, NC | Atrium Health & SAB Lung Nodule Conference

Precision Med TriCon (PMTC)

• Presentation on "Accelerating Drug Development in Prostate Cancer Using MRD as an Endpoint".

9^th Annual Liquid Biopsy for Precision Oncology Summit

• Panel Discussion moderated by Matthew Pink, VP Business Development, Biodesix: Harnessing MRD & ctDNA to Inform Clinical Trial Decision Making & Improve Dosage Regimens
• Presentation by Gary Pestano, Ph.D., Chief Development Officer, Biodesix: Empowering Precision Oncology & MRD Monitoring through ctDNA & CTC Analysis – Sponsored by Bio-Rad Laboratories

---

Friends of Cancer Research Advancing the Future of Diagnostics and Regulatory Innovations

• White Paper co-authored Gary Pestano, Ph.D., Biodesix Chief Development Officer and Brianna Phillips, Biodesix VP Quality and Regulatory Affairs: Innovative Validation and Regulatory Processes for Companion Diagnostic Tests for Rare Biomarkers or Indications

AMP 2024 Annual Meeting & Expo

• Presentation by Gary Pestano, Ph.D., Chief Development Officer, Biodesix: Droplet Digital PCR (ddPCR) in Precision Oncology and MRD: Perspectives from the Trenches
• Poster Presentation by Leisa Jackson, Staff Scientist, Biodesix & Gary Pestano, Ph.D., Chief Development Officer, Biodesix: TT037 Development of a Clinical-Grade Droplet Digital PCR Workflow for Blood-Based Detection of Cancer Relevant miRNAs

Droplet Digital and ddPCR are trademarks of Bio-Rad Laboratories, Inc.

---

ISPOR Europe 2024 Poster presentations by Kimberly Le, PharmD, Director of Health Economics Outcomes Research, Biodesix:

• EPH31: Incidence of Pulmonary Nodules (PNs) During the Coronavirus Disease (COVID-19) Pandemic in the United States (US)
• EPH93: Prevalence of Pulmonary Nodules (PNs) in 2020 During the Coronavirus Disease (COVID-19) Pandemic in the United States (US)
• EE438: Economic Impact Model to Estimate the Value of Blood-Based Biomarkers in the Risk Assessment of Pulmonary Nodules (PNS) From a Health System Perspective
• EPH208: Prevalence of Pulmonary Nodules (PNs) in 2019 in the United States (US)
• EHP209: Incidence of Pulmonary Nodules (PNs) in 2019 in the United States (US)
• CO183: Clinical Impact Model for Blood-Based Biomarkers in the Risk Assessment of Pulmonary Nodules (PNs) From a Health System Perspective

---

AACR Special Conference in Cancer Research: Liquid Biopsy: From Discovery to Clinical Implementation

• Poster Presentation by Colin McDowell, Ph.D. Senior Manager of Business Development, Biodesix: A032 Performance evaluation of a new protein stabilizing blood collection tube with a novel whole blood separation device for clinical plasma proteomics

CHEST 2024 Annual Meeting CHEST Learning Theater Presentation by Sonali Sethi, MD, FCCP, Pulmonary Medicine, Cleveland Clinic and D. Kyle Hogarth, MD, FCCP, Professor of Medicine, University of Chicago: “Patient impact & case studies - the real-world value of biomarkers in lung nodule management”

Go2 for Lung Cancer Centers of Excellence (COE) Summit

---

Droplet Digital PCR World 2024 Asia

• Presentation by Gary Pestano, Ph.D., Chief Development Officer, Biodesix:From Feasibility to Clinical Testing for Rare Variants in Oncology: 10 years of ddPCR Experiences